Related Experiment Video
Updated: Jun 11, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
IPVS STATEMENT on HPV vaccination: No longer supply constraints: Towards achieving WHO vaccine targets
Suzanne M Garland1, Neerja Bhatla2, Yin Ling Woo3
1Reproductive & Neonatal Infectious Diseases, Department of Obstetrics and Gynaecology, University of Melbourne, Director Centre Women's Infectious Diseases Research, Honorary Research Fellow, Infection & Immunity, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
Abstract:
The global supply of human papillomavirus (HPV) prophylactic vaccines has been constrained since 2020.Vaccine manufacturers have increased capacity and new HPV vaccines are now available. Vaccine supply is now able to meet the full HPV vaccine demand which has been achieved earlier than predicted.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
International Nursing Organizations II
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Primary Healthcare Services
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...

